**INTRODUCTION**

Acute myeloid leukaemia (AML) is a blood cancer characterized by clonal myeloid precursors in bone marrow (BM), leading to haematopoiesis failure. Clinical outcome of AML is highly heterogeneous, survive time from days to cure. Cytogenetic abnormalities and gene mutations obtained at the diagnosis time provide the most important information. Recently, aberrant gene expression has also been found to be associated with prognosis in AML, such as BAALC, MN1, ERG, and WT1. Therefore, identification of newly developed biomarkers and construction of molecular-based prognostic risk scores could more precisely recognize the patients who are at high risk, and finally give intensive treatment to improve their clinical outcome.

---

**Abstract**

It has been demonstrated that neural precursor cell expressed developmentally downregulated protein (NEDD) plays crucial roles in tumorigenesis and may serve as potential biomarkers in cancer diagnosis and prognosis. However, few studies systematically investigated the expression of NEDD family members in acute myeloid leukaemia (AML). We systemically determined the expression of NEDD family members in AML and determined their clinical significance. We identified that NEDD9 expression was the only member among NEDD family which was significantly increased in AML. NEDD9 overexpression was more frequently classified as FAB-M4/M5 (p = 0.008 and 0.013, respectively), hardly as FAB-M2/M3. Moreover, NEDD9 overexpression was significantly associated with complex karyotype and TP53 mutation. The significant association between NEDD9 overexpression and survival was also observed in whole-cohort AML and non-M3 AML patients. Notably, AML patients with NEDD9 overexpression may benefit from hematopoietic stem cell transplantation (HSCT), whereas those cases without NEDD9 overexpression did not. Finally, a total of 822 mRNAs and 31 microRNAs were found to be differentially expressed between two groups. Among the microRNAs, miR-381 was also identified as a microRNA that could direct target NEDD9. Taken together, our findings demonstrated that NEDD9 overexpression is associated with genetic abnormalities as well as prognosis and might act as a potential biomarker guiding the choice between HSCT and chemotherapy in patients with AML after achieving complete remission.

**KEYWORDS**

AML, expression, NEDD9, prognosis
NEDD (neural precursor cell expressed developmentally downregulated protein) family members (NEDD1/NEDD4/NEDD8/NEDD9, NEDD1/4/8/9) function highly heterogeneous during biological progress. NEDD1/4/8 members are seen as E3 ubiquitin ligase that recognizes substrates through protein-protein interactions. NEDD9 is initially identified by its developmentally regulated expression pattern in the early embryonic, but not adult, mouse brain. Dysregulation of NEDD family members has been reported in diverse human cancers. For instance, Fujita et al revealed that NEDD1 expression silencing by siRNA might provide a new opportunity in the treatment of the peritoneal metastasis of scirrhous gastric cancer. NEDD4 is widely studied and mostly functions as an oncogene in human cancers, such as gastric cancer, colorectal cancer, lung adenocarcinoma, non-small-cell lung carcinoma, hepatocellular carcinoma, breast cancer, and endometrial cancer. Oncogenic role of NEDD8 has been demonstrated in diverse human cancers. Notably, NEDD8 activates enzyme inhibitor MLN4924 (pevonedistat) has been used in clinical treatment of AML, NEDD9, as a member of the CAS family of adhesion docking proteins, plays a key role in regulating several signalling cascades related to multiple activities, including migration, adhesion, cell death or proliferation. Overexpression of NEDD9 has now been strongly linked to poor prognosis in various types of cancers, as well as resistance to first-line chemotherapeutics. However, NEDD9 exhibits opposite effects regarding migratory capacity on myeloid cells as compared to epithelial or lymphoid cells, which block migration and dissemination of neoplastic cells of the myeloid lineage, while stimulating the increased number of granulocytes in peripheral blood, a hyperplasia of B lymphocytes in peripheral blood and secondary lymphoid organs, yielding an almost complete loss of marginal zone B cells in the spleen. NEDD9-deficient p210-BCR/ABL transgenic mice show an increased number of granulocytes in peripheral blood, a hyperplasia of myeloid and megakaryocytic cells in the bone marrow and a diffuse myeloid infiltration in the spleen, lung and liver, leading to earlier progression and shorter mouse survival, which support NEDD9 capacity to block chronic myeloid leukaemia (CML) progression. There are few studies on the association of NEDD9 and AML.

Herein, as far as known, we for the first time identified and verified that NEDD9 expression, among NEDD family members, was significantly increased in AML. NEDD9 overexpression was correlated with specific cytogenetic and genetic abnormalities of AML. Moreover, NEDD9 overexpression predicts poor clinical outcome in AML and might act as a potential biomarker guiding treatment selection between chemotherapy and hematopoietic stem cell transplantation (HSCT) as consolidation therapy.

2 | MATERIALS AND METHODS

2.1 | GEPIA analysis

The Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepi.a.cancer-pku.cn/) provides RNA-sequencing expression data of 9,736 tumours and 8587 normal samples from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects, using a standard processing pipeline. The expression of NEDD family members between AML and control was identified by GEPIA.

2.2 | TCGA data

A total of 173 AML patients with RNA-sequencing data from the databases of TCGA were included in this study. NEDD family member expression data of these patients were obtained by mRNA sequencing. Mutation data of these patients were also obtained by DNA sequencing. Clinical characteristics and treatment regimens of these patients were also obtained.

2.3 | Bioinformatic analysis

To obtain the differential expressed genes (DEGs), analysis of RNA-sequencing (mRNA and microRNA) data was calculated using the raw read counts with the R/Bioconductor package `edgeR`. All analyses were controlled for the false discovery rate (FDR) by the Benjamini-Hochberg procedure. Functional and signalling pathway enrichments were analysed through the STRING (http://string-db.org). NEDD9 targeted by microRNA was identified by DIANA (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=miroT_CDS/index), miRDB (http://mirdb.org/miRDB/), TargetScan (http://www.targetscan.org/vert_72/) and starBase (http://starbase.sysu.edu.cn/).

2.4 | Statistical analysis

Student t/Mann–Whitney U/Kruskal–Wallis H test and Pearson's $\chi^2$/Fisher's exact test were applied for the comparison of continuous and categorical variables, respectively. The effect of NEDD family member expression on overall survival (OS) and leukaemia-free survival (LFS) was analysed by the Kaplan-Meier method (log-rank test). Two-sided p-values less than 0.05 in all statistical analyses were considered as statistically significant differences.

3 | RESULTS

3.1 | Expression of NEDD family in AML

In order to investigate the NEDD family (NEDD1/4/8/9) expression patterns in AML, we first used the AML cohort from public databases by GEPIA online website. The AML patients were from the TCGA data sets, whereas normal controls were from the GTEx projects. The expression of NEDD1/4/8 showed no significant differences between AML and controls (Figure 1A-C). However, NEDD9 expression was markedly increased in AML (Figure 1D).
3.2 | Clinical implications of NEDD9 expression in AML

Since NEDD9 was the only one member of NEDD family to be aberrantly expressed in AML, we further analysed the correlations of abnormal NEDD9 expression (above the median level) with the clinical/biological characteristics. As shown in Table 1, AML cases with NEDD9 overexpression had a markedly older age than those without NEDD9 overexpression (p = 0.003). Interestingly, NEDD9 overexpressed patients had significantly lower peripheral blood blasts than NEDD9 underexpressed patients (p < 0.001). Moreover, significant differences in the distribution of FAB (French-American-British) classification and cytogenetics were found between NEDD9 overexpressed and underexpressed groups (both p = 0.001). NEDD9 overexpression was more frequently classified as FAB-M4/M5 (p = 0.008 and 0.013, respectively), hardly as FAB-M2/M3 (p = 0.043 and 0.063, respectively). Notably, the frequency of NEDD9 overexpression in the monocytic line subtype (M4/M5) (38/52, 73.1%) was significantly higher than all the other subtypes (48/121, 39.7%) (p < 0.001), whereas the frequency of NEDD9 overexpression in granulocytic line subtype (M0/M1/M2/M3) (43/114, 37.7%) was markedly lower than all the other subtypes (43/59, 72.9%) (p < 0.001). Moreover, NEDD9 overexpression was significantly associated with complex karyotype (p < 0.001). Moreover, NEDD9 expression pattern was further compared among different FAB subtypes and karyotypes (Figure 2A,B). Among gene mutations, NEDD9 overexpression was significantly correlated with TP53 mutation (p = 0.001). Additionally, NEDD9 expression was further compared between the mutant and wild-type groups of these genes (TP53 and NRAS) (Figure 2C,D).

3.3 | Prognostic value of NEDD9 expression in AML

To explore the prognostic value of NEDD9 expression in AML, Kaplan-Meier analysis was performed and revealed that AML patients with NEDD9 overexpression presented significantly shorter OS and LFS time than those without NEDD9 overexpression (Figure 3). Moreover, if FAB-M3/t(15;17) patients were excluded, non-M3 AML cases with NEDD9 overexpression still showed markedly shorter OS and LFS time than those without NEDD9 overexpression (Figure 3). In addition, we further analysed the prognostic value of the other NEDD family (NEDD1/4/8) expression in AML. However, significantly prognostic effect of NEDD1/4/8 expression was not identified in AML.

3.4 | Guidance value of NEDD9 expression in AML

HSCT as a consolidation treatment regimen is of great importance in AML against disease recurrence. To investigate whether HSCT might overcome the adverse prognostic effect caused by NEDD9 overexpression in AML, we analysed the prognostic impact of HSCT in NEDD9 overexpressed and underexpressed groups, respectively. After AML patients achieved CR, cases undergoing HSCT exhibited markedly longer OS and LFS compared with that only receiving chemotherapy in NEDD9 overexpressed group. However, in NEDD9 underexpressed group, there were no significant differences regarding OS and LFS between HSCT and chemotherapy groups (Figure 4). These results suggested that AML patients with NEDD9 overexpression may benefit from HSCT, and NEDD9 expression might act as a potential biomarker guiding treatment selection between HSCT and chemotherapy in patients with AML after achieving CR by induction therapy.

3.5 | Biological network of NEDD9 expression in AML

To get better understanding of the biological network associated with NEDD9 expression in AML, we first compared the transcriptomes of NEDD9 overexpression and underexpression groups in AML among TCGA cohorts. Based on the filter condition: |log2
### Patient’s parameters

|                      | NEDD9 expression | p Value |
|----------------------|------------------|---------|
|                      | Low (n = 87)     | High (n = 86) |          |
| Sex, male/female     | 42/45            | 50/36    | 0.224   |
| Median age, years (range) | 55 (18–82)   | 62 (23–88) | 0.003   |
| Median WBC, $\times 10^9$/L (range) | 17.9 (0.4–297.4) | 15.6 (0.7–137.2) | 0.189   |
| Median PB blasts, % (range) | 49 (0–98)     | 17 (0–90) | 0.000   |
| Median BM blasts, % (range) | 75 (33–100)   | 71 (30–97) | 0.099   |

### FAB classifications

|        |     |     |
|--------|-----|-----|
| M0     | 7   | 9   |
| M1     | 27  | 17  |
| M2     | 25  | 13  |
| M3     | 12  | 4   |
| M4     | 10  | 24  |
| M5     | 4   | 14  |
| M6     | 0   | 2   |
| M7     | 1   | 2   |
| No data| 1   | 1   |

### Cytogenetics

|             |     |     |
|--------------|-----|-----|
| Normal       | 41  | 39  |
| t(15;17)     | 11  | 4   |
| t(8;21)      | 6   | 1   |
| inv(16)      | 7   | 3   |
| +8           | 7   | 1   |
| del(5)       | 1   | 0   |
| −7/del(7)    | 3   | 4   |
| 11q23        | 1   | 2   |
| Others       | 4   | 10  |
| Complex      | 4   | 21  |
| No data      | 2   | 1   |

### Gene mutation

|         |     |     |         |
|---------|-----|-----|---------|
| FLT3 (+/-) | 27/60 | 22/64 | 0.500   |
| NPM1 (+/-) | 25/62 | 23/63 | 0.865   |
| DNMT3A (+/-) | 20/67 | 22/64 | 0.725   |
| IDH2 (+/-) | 7/80  | 10/76 | 0.456   |
| IDH1 (+/-) | 10/77 | 6/80  | 0.423   |
| TET2 (+/-) | 8/79  | 7/79  | 1.000   |
| RUNX1 (+/-) | 6/81  | 9/77  | 0.407   |
| TP53 (+/-) | 1/86  | 13/73 | 0.001   |
| NRAS (+/-) | 3/84  | 9/77  | 0.080   |
| CEBPA (+/-) | 8/79  | 5/81  | 0.566   |
| WT1 (+/-) | 7/80  | 3/83  | 0.329   |
| PTPN11 (+/-) | 4/83  | 4/82  | 1.000   |
| KIT (+/-) | 4/83  | 3/83  | 1.000   |
| U2AF1 (+/-) | 4/83  | 3/83  | 1.000   |
| KRAS (+/-) | 3/84  | 4/82  | 0.720   |

**Abbreviations:** AML, acute myeloid leukaemia; BM, bone marrow; FAB, French-American-British; NS, no significance; PB, peripheral blood; WBC, white blood cells.
A total of 822 genes including 588 upregulated and 234 downregulated (high vs low) were found to be differentially expressed between two groups (Figure 5A, B and Table S1). The top 10 upregulated genes such as FEZ1 and PDK4 are reported with proto-leukaemia effects.\textsuperscript{27,28} Furthermore, the Gene Ontology analysis revealed that these genes involved in biologic processes, including multicellular organismal process, cell communication and signalling (Figure 5C).
Moreover, we also compared the microRNA expression pattern between NEDD9 overexpression and underexpression groups. A total of 31 microRNAs including 6 upregulated and 25 downregulated were found to be differentially expressed between two groups (Figure 5D and Table S1). Downregulated microRNAs such as miR-135a, miR-203, miR-497, miR-381, miR-370 and miR-758 were found to be underexpressed in AML or have anti-leukaemia effects in previous reports.29–35 Of these microRNAs, miR-381 was also identified as a microRNA that could direct target NEDD9 (Figure 5E and Table S2), which suggested NEDD9 is a direct target of miR-381.

4 | DISCUSSION

It has been determined that NEDD9 plays a crucial role in regulating several signalling cascades contained in multiple activities, including cell apoptosis or proliferation, migration, invasion, metastasis and adhesion.7 Moreover, overexpression of NEDD9 correlated with cancer cell development and drug resistance in several types of solid tumours such as lung cancer, melanoma and breast cancer.8 It is not surprising that aberrant NEDD9 expression has been linked to the prognosis of human cancers.1,20

In this study, we for the first time revealed that NEDD9 overexpression, identified from NEDD family, was associated with poor prognosis in AML. Notably, NEDD9 expression might act as a potential biomarker predicting prognosis and guiding treatment choice between chemotherapy and HSCT in AML. Until now, few investigations have reported the links between NEDD9 and AML. In contrary to our results, Pallarès et al demonstrated that NEDD9 was an independent good prognostic factor in intermediate-risk AML patients.24 The possible reason was that the previous report only included AML patients less than 65 years. As it is well known, AML is an ageing disease which contains larger numbers of older patients. Accordingly, further clinical and functional studies are needed to evaluate the clinical implication and potential role of NEDD9 in AML.

Our study also found significant associations between NEDD9 expression and FAB classifications as well as cytogenetic/genetic subtypes in AML. For FAB classifications, NEDD9 overexpression was associated with FAB-M4/M5 in accordance with previous studies,24 and results analysed by BloodSopt (https://servers.binf.ku.dk/bloodspot/) show that NEDD9 expression is significantly higher in monocytic lineages, suggesting it may play a crucial role in monocytic line development (Figure S1). For cytogenetic/genetic subtypes, NEDD9 overexpression was found to be strongly correlated with
complex karyotype and TP53 mutations. Since TP53 mutation is frequently occurred in the complex karyotype, it is difficult to classify which is mainly the factor associated with NEDD9 overexpression. Interestingly, previous studies have determined the association of TP53 with NEDD9 in non-small-cell lung cancer. Moreover, we also confirmed that TP53 could bind the NEDD9 promoter with a...
predicted sequence ACCAGCTCAAACATT by analysing JASPAR (http://jaspar.genereg.net/). These results demonstrated that NEDD9 overexpression plays a key role in leukaemogenesis caused by complex karyotype and/or TP53 mutations. Further studies are required to determine the underlying mechanism of NEDD9 expression in AML with complex karyotype and TP53 mutations.

NEDD9 regulated by microRNAs has been reported by several studies. MiR-25-5p directly targeting NEDD9 was found in oral squamous cell carcinoma and colorectal cancer. Moreover, NEDD9 expression regulated by miR-145 was revealed in lung cancer, pancreatic cancer, renal cell carcinoma, prostate cancer and glioblastoma. Additionally, NEDD9 expression negatively associated with miR-125a/b was shown in pancreatic cancer, lung adenocarcinoma and melanoma. In pancreatic cancer and hepatocellular carcinoma, NEDD9 was reported to be regulated by mir-18a playing a key role during carcinogenesis. In our study, we for the first time found that NEDD9 expression was negatively associated with miR-381 in AML. However, the limitation in our study was that luciferase assay was not performed to verify the direct associations between miR-381 and NEDD9. Therefore, a number of investigations are needed to confirm our results in the future.

Collectively, our findings demonstrated that NEDD9 overexpression associated with genetic abnormalities as well as prognosis might act as a potential biomarker guiding the choice between HSCT and chemotherapy in patients with AML.

ACKNOWLEDGEMENTS
None.

CONFLICT OF INTEREST
The authors confirm that there are no conflicts of interest.

AUTHOR CONTRIBUTIONS
Shenghao Hua: Conceptualization (equal); Writing-original draft (equal). tao feng: Methodology (supporting); Writing-review & editing (supporting). lei yin: Methodology (supporting); Software (supporting); Writing-review & editing (supporting). qi wang: Methodology (supporting); Writing-review & editing (supporting). xuejun shao: Conceptualization (equal); Investigation (equal); Project administration (equal); Resources (equal).

ORCID
Xuejun Shao https://orcid.org/0000-0002-4853-2634

REFERENCES
1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152.
2. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
3. Handschuh L. Not only mutations matter: molecular picture of acute myeloid leukemia emerging from transcriptome studies. J Oncol. 2019;2019:7239206.
4. Manning J, Kumar S. NEDD1: function in microtubule nucleation, spindle assembly and beyond. Int J Biochem Cell Biol. 2007;39(1):7-11.
5. Wang ZW, Hu X, Ye M, Lin M, Chu M, Shen X. NEDD4 E3 ligase: Functions and mechanism in human cancer. Semin Cancer Biol. 2020;67(Pt 2):92-101.
6. Gai W, Peng Z, Liu CH, Zhang L, Jiang H. Advances in cancer treatment by targeting the neddylation pathway. Front Cell Dev Biol. 2021;9:653882.
7. Zhang S, Wu L. Roles of neural precursor cell expressed, developmentally downregulated 8 promotes tumor formation and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation. RNA Biol. 2021:1-15. [Epub ahead of print].
8. Tian DW, Wu ZL, Jiang LM, Gao J, Wu CL, Hu HL. Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer. Cancer Sci. 2019;110(1):458-467.
9. Huang J, Zhou Y, Thomas GS, et al. NEDD8 Inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma. Clin Cancer Res. 2015;21(24):5532-5542.
10. Swords RT, Erba HP, DeAngelo DJ, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169(4):534-543.
11. NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131(13):1415-1424.
12. Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/MMML or low-blast AML. Leukemia. 2021;35(7):2119-2124.
13. Singh M, Cowell L, Seo S, O’Neill G, Golemis E. Molecular basis for HIF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007;48(1):54-72.
14. Nikonova AS, Gaponova AV, Kudinov AE, Golemis EA. CAS proteins in health and disease: an update. IUBMB Life. 2014;66(6):387-395.
15. Gu Y, Lu J, Chen C, Zheng F. NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis. Onco Targets Ther. 2019;12:4213-4222.
16. Izumchenko E, Singh MK, Plotnikova OV, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009;69(18):7198-7206.
17. Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/MMML or low-blast AML. Leukemia. 2021;35(7):2119-2124.
18. Singh M, Cowell L, Seo S, O’Neill G, Golemis E. Molecular basis for HIF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle. Cell Biochem Biophys. 2007;48(1):54-72.
19. Nikonova AS, Gaponova AV, Kudinov AE, Golemis EA. CAS proteins in health and disease: an update. IUBMB Life. 2014;66(6):387-395.
20. Gu Y, Lu J, Chen C, Zheng F. NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis. Onco Targets Ther. 2019;12:4213-4222.
21. Izumchenko E, Singh MK, Plotnikova OV, et al. NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res. 2009;69(18):7198-7206.
22. Seo S, Asai T, Saito T, et al. Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance. J Immunol. 2005;175(6):3492-3501.
23. Seo S, Nakamoto T, Takeshita M, et al. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl. Cancer Sci. 2011;102(12):2109-2117.
24. Pallarès V, Hoyos M, Chillón MC, et al. NEDD9, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patients. Oncotarget. 2017;8(44):76003-76014.

25. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-W102.

26. Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.

27. Bertini Teixeira M, Figueira ACM, Furlan AS, et al. Fasciculation and elongation zeta-1 protein (FEZ1) interacts with the retinoic acid receptor and participates in transcriptional regulation of the Hoxb4 gene. FEBs Open Bio. 2017;8(1):4-14.

28. Duan XL, Ma CC, Hua J, Xiao TW, Luan J. Benzyl butyl phthalate (BBP) triggers the malignancy of acute myeloid leukemia cells via upregulation of PDK4. Toxicol In Vitro. 2020;62:104693.

29. Xu H, Wen Q. Downregulation of miR-135a predicts poor prognosis in acute myeloid leukemia and regulates leukemia progression via modulating HOXA10 expression. Mol Med Rep. 2018;18(1):1134-1140.

30. Zhang Y, Zhou SY, Yan HZ, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep. 2016;6:19995.

31. Nie ZY, Zhao MH, Cheng BQ, et al. Tanshinone IIA regulates human AML cell proliferation, cell cycle, and apoptosis through miR-497-5p/AKT3 axis. Cancer Cell Int. 2020;20:379.

32. Zhang P, Sun D, Sun X, Li H. Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia. Eur J Med Res. 2020;25(1):42.

33. Zhang X, Zeng J, Zhou M, et al. The tumor suppressive role of miR-NA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 2012;11:56.

34. Lin X, Wang Z, Wang Y, Feng W. Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia. Int J Clin Exp Pathol. 2015;8(11):14658-14666.

35. Xiao Y, Ming X, Wu J. Hsa_circ_0002483 regulates miR-758-3p/MYC axis to promote acute myeloid leukemia progression. Hematol Oncol. 2021;39(2):243-253.

36. Molica M, Mazzone C, Niscola P, de Fabritiis P. TP53 mutations in acute myeloid leukemia: still a daunting challenge? Front Oncol. 2021;11:610820.

37. Rousseau B, Jacquot C, Le Palabe J, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5:10356.

38. Wang Y, Tao B, Li J, Mao X, He W, Chen Q. Melatonin inhibits the progression of oral squamous cell carcinoma via inducing miR-25-5p expression by directly targeting NEDD9. Front Oncol. 2020;10:543591.

39. Jung JH, Shin EA, Kim JH, et al. NEDD9 inhibition by miR-25-5p activation is critically involved in co-treatment of melatonin- and pterostilbene-induced apoptosis in colorectal cancer cells. Cancers. 2019;11(11):1684.

40. Yu W, Ding J, He M, et al. Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene. 2019;38(8):1225-1238.

41. Han T, Yi XP, Liu B, Ke MJ, Li YX. MicroRNA-145 suppresses cell proliferation, invasion and migration in pancreatic cancer cells by targeting NEDD9. Mol Med Rep. 2015;11(6):4115-4120.

42. Lu R, Ji Z, Li X, et al. miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J Cancer Res Clin Oncol. 2014;140(3):387-397.

43. Guo W, Ren D, Chen X, et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem. 2013;114(7):1606-1615.

44. Speranza MC, Frattini V, Pisati F, et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012;3(7):723-734.

45. Xue Y, Zhong Y, Wu T, et al. Anti-proliferative and apoptosis-promoting effect of microRNA-125b on pancreatic cancer by targeting NEDD9 via PI3K/AKT signaling. Cancer Manag Res. 2020;12:7363-7373.

46. Zheng H, Wu J, Shi J, et al. miR-125a-5p upregulation suppresses the proliferation and induces the cell apoptosis of lung adenocarcinoma by targeting NEDD9. Oncol Rep. 2017;38(3):1790-1796.

47. Rambow F, Bechadergue A, Luciani F, et al. Regulation of melanoma progression through the TCF4/miR-125b/NEDD9 cascade. J Invest Dermatol. 2016;136(6):1229-1237.

48. Zheng Y, Nie P, Xu S. Long noncoding RNA linc00467 plays an oncogenic role in hepatocellular carcinoma by regulating the miR-18a-5p/NEDD9 axis. J Cell Biochem. 2020;121(5-6):3135-3144.

49. Li X, Zhang Z, Li Y, et al. miR-18a-5p/NEDD9 axis. J Cell Biochem. 2016;117(11):4202-4208.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Hua S, Feng T, Yin L, Wang Q, Shao X. NEDD9 overexpression: Prognostic and guidance value in acute myeloid leukaemia. J Cell Mol Med. 2021;25:9331–9339. https://doi.org/10.1111/jcmm.16870